Freenome's updated blood test shows stronger detection of precancerous lesions, boosting Abbott's market prospects

Freenome announced that its revised SimpleScreen CRC blood test met both primary and secondary goals in a pivotal validation study. The new data indicate better performance than the earlier version, especially in identifying precancerous growths.

The company highlighted that the improved results position Abbott, its commercial partner since last August, to become a leading player in colorectal cancer screening once the test receives FDA clearance.

Analysts at Evercore ISI noted that Abbott could dominate the market, competing with Guardant Health's Shield test, the first FDA‑approved blood‑based colorectal cancer screen for average‑risk adults.